Prana Biotechnology ADR
WKN: A2AFT0 / ISIN: US7397272045Führend in Alzheimer Forschung! PRANA Biotech.
| eröffnet am: | 15.04.04 20:24 von: | geldschneider |
| neuester Beitrag: | 24.04.21 23:59 von: | Stefaniepyzja |
| Anzahl Beiträge: | 150 | |
| Leser gesamt: | 33803 | |
| davon Heute: | 1 | |
bewertet mit 2 Sternen |
||
|
Seite:
1
|
2
|
||
30.04.04 13:46
#26
Nussriegel
@ optimal
muss ja vielleicht auch nicht jedesmal extra dazu gesagt werden, weils eben selbstverständlich ist.
aber diese Spielchen "schreibst du `risikoreich` in meinen Thread, schreib ich es in deinen"
und "ich mach dich fertig, weil ich mehr IDs hab als Du"
sind doch Kindergartenkram.
Das könnte man doch unter Erwachsenen OPTIMALer lösen, oder?
aber diese Spielchen "schreibst du `risikoreich` in meinen Thread, schreib ich es in deinen"
und "ich mach dich fertig, weil ich mehr IDs hab als Du"
sind doch Kindergartenkram.
Das könnte man doch unter Erwachsenen OPTIMALer lösen, oder?
01.05.04 18:22
#27
geldschneider
An Kindergarten hab` ich auch gedacht
als ich die Beiträge von Fragezeichen las!
Nur habe ich gar nichts von risikoreich geschrieben, sondern nur das ich froh bin, nicht beim Down dabei zu sein und das Geld von GPC und mehr nochmal in Prana investiert habe, und dass ich es gut finde, wenn Forst Falkenau, die Begeisterung für GPC mal bremst!
Das hat ihn so geärgert, dass er nun meinen Wert überall niedermacht!
da konnte ich nicht umhin auch bei GPC darauf aufmerksam zu machen, dass schließlich alle Biotech Aktien sehr spekulativ sind!
Denn GPC ist mit dem einen Medikament in der Pipeline, nicht sehr stabil, aber doch schon sehr teuer!
Wer sich für biotech interessiert, der sollte auf mehrere biotech-Werte setzen und vor allem auf welche, die noch mehr Kurschancen aufweisen, wie ich das bei Prana Biotech sehe!
Und in der Krebs-Forschung sind eine Unmenge an Firmen tätig, aber Alzheimer ist eine Erkrankung, die nicht wie Krebs zum Tode führt sondern zu einem Pflegefall und einer langsamen aber sicheren VErblödung führt, deshalb finde ich die Forschung in diesem Bereich sehr wichtig, weil es wie Parkinson, eine sehr häufige Alterserkrankung ist!
Meine Großmutter hat unter ihrer Parkinson-Erkrankung sehr gelitten und sie wäre froh gewesen, wenn sie nicht mehr hätte weiterleben müssen! Außer mir hat das niemand gewußt, weil ihre Söhne mit ihr gar nicht mehr kommunzieren konnten, weil sie sehr lange brauchte, bis sie wußte wer der Besucher war! Mein Onkel (ihr Sohn) erzählte, er könne mit ihr nichts mehr anfangen, weil sie nicht wüßte wer er sei!!
Ich hoffe dass Prana, ERfolg mit diesem Medikament hat, und dass es zugelassen wird!!
Es würde vielleicht manche vor einem Pflegeheim bewahren!
Nur habe ich gar nichts von risikoreich geschrieben, sondern nur das ich froh bin, nicht beim Down dabei zu sein und das Geld von GPC und mehr nochmal in Prana investiert habe, und dass ich es gut finde, wenn Forst Falkenau, die Begeisterung für GPC mal bremst!
Das hat ihn so geärgert, dass er nun meinen Wert überall niedermacht!
da konnte ich nicht umhin auch bei GPC darauf aufmerksam zu machen, dass schließlich alle Biotech Aktien sehr spekulativ sind!
Denn GPC ist mit dem einen Medikament in der Pipeline, nicht sehr stabil, aber doch schon sehr teuer!
Wer sich für biotech interessiert, der sollte auf mehrere biotech-Werte setzen und vor allem auf welche, die noch mehr Kurschancen aufweisen, wie ich das bei Prana Biotech sehe!
Und in der Krebs-Forschung sind eine Unmenge an Firmen tätig, aber Alzheimer ist eine Erkrankung, die nicht wie Krebs zum Tode führt sondern zu einem Pflegefall und einer langsamen aber sicheren VErblödung führt, deshalb finde ich die Forschung in diesem Bereich sehr wichtig, weil es wie Parkinson, eine sehr häufige Alterserkrankung ist!
Meine Großmutter hat unter ihrer Parkinson-Erkrankung sehr gelitten und sie wäre froh gewesen, wenn sie nicht mehr hätte weiterleben müssen! Außer mir hat das niemand gewußt, weil ihre Söhne mit ihr gar nicht mehr kommunzieren konnten, weil sie sehr lange brauchte, bis sie wußte wer der Besucher war! Mein Onkel (ihr Sohn) erzählte, er könne mit ihr nichts mehr anfangen, weil sie nicht wüßte wer er sei!!
Ich hoffe dass Prana, ERfolg mit diesem Medikament hat, und dass es zugelassen wird!!
Es würde vielleicht manche vor einem Pflegeheim bewahren!
15.05.04 16:54
#28
geldschneider
Neues Research über Alzheimer Erkrankung
Welche Rolle Prana spielt, bei der Behandlung von Alzheimer??
Latest News
--------------------------------------------------
(Printer friendly version) New Research Suggests Additional Role for Prana Technology Against Alzheimer's Disease
MELBOURNE, Australia, May 3, 2004 /PRNewswire-FirstCall via COMTEX/ -- The
Journal of Biological Chemistry has published findings by researchers for Prana
Biotechnology Limited (Nasdaq: PRAN; ASX: PBT) suggesting an additional
mechanism for the action of Prana's technology in delaying the progress and
severity of Alzheimer's disease.
Prana's MPACs (metal protein attenuating compounds) have previously been shown
to lower the levels of beta-amyloid in the brain -- the main component of
amyloid plaques that are a feature of Alzheimer's disease. The new research
suggests that that these MPACs may also be effective in preventing beta-amyloid
from attaching itself to and damaging COX-2, the key enzyme that mediates
inflammation in the brain often associated with Alzheimer's disease. Levels of
beta amyloid/COX-2 complexes were found to be elevated significantly in the
brains of patients with Alzheimer's disease.
Professor Ashley Bush of Harvard Medical School and Chief Scientific Consultant
to Prana was the senior author on the paper: "COX-2 has been implicated in
Alzheimer's disease, but studies of COX-2 inhibitors (anti- inflammatory drugs)
have been disappointing. Our current findings explain how the interaction of
beta-amyloid with brain copper corrupts the normal metabolism of COX-2 in
Alzheimer's disease. These findings further validate Prana's MPAC drug approach,
which targets the adverse metal interaction with amyloid. MPACs stop the
beta-amyloid/metal complex from damaging COX-2. These findings also may explain
why anti-inflammatory drugs would not be effective in Alzheimer's disease."
An abstract of the article can be read online at
http://www.jbc.org/cgi/content/abstract/279/15/14673
About Prana Biotechnology Limited
Based in Australia, incorporated in 1997 and listed on the Australian Stock
Exchange in March 2000, Prana Biotechnology (NASDAQ: PRAN; ASX: PBT) was
established to commercialize research into Alzheimer's disease and other major
age-related degenerative disorders. Its mission is to develop diagnostic and
therapeutic drugs to treat the central disease pathways that cause degeneration
of the brain as the aging process progresses. Prana's technology has emerged
from its researchers at prominent international institutions such as
Massachusetts General Hospital at Harvard Medical School and the University of
Melbourne. For further information, please visit our web site at
www.pranabio.com.
This press release contains "forward looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995 regarding the Company's
business strategy and future plans of operation. Forward-looking statements
involve known and unknown risks and uncertainties; both general and specific to
the matters discussed in this press release. These and other important factors,
including those mentioned in various Securities and Exchange Commission filings
made by the Company, may cause the Company's actual results and performance to
differ materially from the future results and performance expressed in or
implied by such forward-looking statements. The forward-looking statements
contained in this press release speak only as of the date hereof and the Company
expressly disclaims any obligation to provide public updates, revisions or
amendments to any forward-looking statements made herein to reflect changes in
the Company's expectations or future events.
SOURCE Prana Biotechnology Limited
CONTACT: Geoffrey Kempler of Prana Biotechnology Limited,
+61-3-9690-7892, gkempler@pranabio.com; or Media and Investor, US - Ivette
Almeida, ivette.almeida@annemcbride.com, or Steven Silver,
silver@annemcbride.com, both of the Anne McBride Company, +1-212-983-1702,
ext. 209, for Prana; or Media, Australia - Kate Mazoudier, +61-1-3-9866-4722,
kmazoudier@bcg.com.au, for Prana
URL: http://www.pranabio.com
http://www.prnewswire.com
Copyright (C) 2004 PR Newswire. All rights reserved.
KEYWORD: Australia
INDUSTRY KEYWORD: MTC
HEA
BIO
So vor lauter GPC Streit, habe ich vergessen die News reinzustellen, würde mich aber mal freuen, wenn andere auch mitachen würden!
Wenn Alzheimer nicht wichtig erscheint, dann kannich es ja bleiben lassen!
Die Einmann Show liegt mir nicht!
Latest News
--------------------------------------------------
(Printer friendly version) New Research Suggests Additional Role for Prana Technology Against Alzheimer's Disease
MELBOURNE, Australia, May 3, 2004 /PRNewswire-FirstCall via COMTEX/ -- The
Journal of Biological Chemistry has published findings by researchers for Prana
Biotechnology Limited (Nasdaq: PRAN; ASX: PBT) suggesting an additional
mechanism for the action of Prana's technology in delaying the progress and
severity of Alzheimer's disease.
Prana's MPACs (metal protein attenuating compounds) have previously been shown
to lower the levels of beta-amyloid in the brain -- the main component of
amyloid plaques that are a feature of Alzheimer's disease. The new research
suggests that that these MPACs may also be effective in preventing beta-amyloid
from attaching itself to and damaging COX-2, the key enzyme that mediates
inflammation in the brain often associated with Alzheimer's disease. Levels of
beta amyloid/COX-2 complexes were found to be elevated significantly in the
brains of patients with Alzheimer's disease.
Professor Ashley Bush of Harvard Medical School and Chief Scientific Consultant
to Prana was the senior author on the paper: "COX-2 has been implicated in
Alzheimer's disease, but studies of COX-2 inhibitors (anti- inflammatory drugs)
have been disappointing. Our current findings explain how the interaction of
beta-amyloid with brain copper corrupts the normal metabolism of COX-2 in
Alzheimer's disease. These findings further validate Prana's MPAC drug approach,
which targets the adverse metal interaction with amyloid. MPACs stop the
beta-amyloid/metal complex from damaging COX-2. These findings also may explain
why anti-inflammatory drugs would not be effective in Alzheimer's disease."
An abstract of the article can be read online at
http://www.jbc.org/cgi/content/abstract/279/15/14673
About Prana Biotechnology Limited
Based in Australia, incorporated in 1997 and listed on the Australian Stock
Exchange in March 2000, Prana Biotechnology (NASDAQ: PRAN; ASX: PBT) was
established to commercialize research into Alzheimer's disease and other major
age-related degenerative disorders. Its mission is to develop diagnostic and
therapeutic drugs to treat the central disease pathways that cause degeneration
of the brain as the aging process progresses. Prana's technology has emerged
from its researchers at prominent international institutions such as
Massachusetts General Hospital at Harvard Medical School and the University of
Melbourne. For further information, please visit our web site at
www.pranabio.com.
This press release contains "forward looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995 regarding the Company's
business strategy and future plans of operation. Forward-looking statements
involve known and unknown risks and uncertainties; both general and specific to
the matters discussed in this press release. These and other important factors,
including those mentioned in various Securities and Exchange Commission filings
made by the Company, may cause the Company's actual results and performance to
differ materially from the future results and performance expressed in or
implied by such forward-looking statements. The forward-looking statements
contained in this press release speak only as of the date hereof and the Company
expressly disclaims any obligation to provide public updates, revisions or
amendments to any forward-looking statements made herein to reflect changes in
the Company's expectations or future events.
SOURCE Prana Biotechnology Limited
CONTACT: Geoffrey Kempler of Prana Biotechnology Limited,
+61-3-9690-7892, gkempler@pranabio.com; or Media and Investor, US - Ivette
Almeida, ivette.almeida@annemcbride.com, or Steven Silver,
silver@annemcbride.com, both of the Anne McBride Company, +1-212-983-1702,
ext. 209, for Prana; or Media, Australia - Kate Mazoudier, +61-1-3-9866-4722,
kmazoudier@bcg.com.au, for Prana
URL: http://www.pranabio.com
http://www.prnewswire.com
Copyright (C) 2004 PR Newswire. All rights reserved.
KEYWORD: Australia
INDUSTRY KEYWORD: MTC
HEA
BIO
So vor lauter GPC Streit, habe ich vergessen die News reinzustellen, würde mich aber mal freuen, wenn andere auch mitachen würden!
Wenn Alzheimer nicht wichtig erscheint, dann kannich es ja bleiben lassen!
Die Einmann Show liegt mir nicht!
15.05.04 17:00
#29
geldschneider
Prana wurde in London vorgestellt!
In London gab es ein Treffen von vielen bekannten Biotech Frimen, darunter auch Prana!
Ich hatte auch eine Einladungskarte bekommmen, konnte aber nicht teilnehmen.
MELBOURNE, Australia, May 5, 2004 /PRNewswire-FirstCall via COMTEX/ --
Executive Chairman of Prana Biotechnology Limited (Nasdaq: PRAN; ASX: PBT), Mr
Geoffrey Kempler, has been invited to brief UK investors at the Rodman & Renshaw
Techvest Global Healthcare Conference at Claridge's Hotel in London on Wednesday
May 12, 2004 at 8:40 AM local time.
Prana is an Australian-based biotechnology company focusing on technology that
has shown early promise as a potential treatment for Alzheimer's disease and
other age-related disorders. At the conference, Mr Kempler will provide an
update of Prana's scientific and commercial milestones, including forthcoming
clinical trials for its MPAC technology.
Rodman & Renshaw, a leading investment bank dedicated to emerging growth
companies, was recently agent for Prana Biotechnology's US $20 million placement
to US institutions and professional investors.
To arrange a one-on-one meeting with representatives of Prana Biotechnology
during the conference, please contact Steven Silver at The Anne McBride Company,
tel. 212-983-1702, ext 212, or silver@annemcbride.com.
Ich hatte auch eine Einladungskarte bekommmen, konnte aber nicht teilnehmen.
MELBOURNE, Australia, May 5, 2004 /PRNewswire-FirstCall via COMTEX/ --
Executive Chairman of Prana Biotechnology Limited (Nasdaq: PRAN; ASX: PBT), Mr
Geoffrey Kempler, has been invited to brief UK investors at the Rodman & Renshaw
Techvest Global Healthcare Conference at Claridge's Hotel in London on Wednesday
May 12, 2004 at 8:40 AM local time.
Prana is an Australian-based biotechnology company focusing on technology that
has shown early promise as a potential treatment for Alzheimer's disease and
other age-related disorders. At the conference, Mr Kempler will provide an
update of Prana's scientific and commercial milestones, including forthcoming
clinical trials for its MPAC technology.
Rodman & Renshaw, a leading investment bank dedicated to emerging growth
companies, was recently agent for Prana Biotechnology's US $20 million placement
to US institutions and professional investors.
To arrange a one-on-one meeting with representatives of Prana Biotechnology
during the conference, please contact Steven Silver at The Anne McBride Company,
tel. 212-983-1702, ext 212, or silver@annemcbride.com.
15.05.04 17:04
#30
geldschneider
Prana am 20 Mai in Las VEGAS Healthcare Conference
(Printer friendly version) Prana's Founding Scientist to Present at Banc of America 2004 Healthcare Conference
MELBOURNE, Australia, May 11, 2004 /PRNewswire-FirstCall via COMTEX/ -- Prana
Biotechnology Limited (Nasdaq: PRAN, ASX: PBT) today announced that its founding
scientist Dr. Ashley Bush, of Harvard Medical School, will present at the Banc
of America 2004 Healthcare Conference at The Four Seasons Hotel in Las Vegas on
Thursday, May 20th, 2004, at 8:00 AM PDT.
Dr. Bush's theories concerning the interaction between metals and the protein
beta-amyloid in the brain are the basis of Prana's treatments for Alzheimer's
and other neurodegenerative diseases.
The conference will include both a company presentation and a moderated
discussion between management and institutional investors.
To arrange a one-on-one meeting with Dr. Bush during the conference, please
contact Steven Silver at The Anne McBride Company, tel. 212-983-1702, ext 212,
or silver@annemcbride.com.
About Prana
Prana is a Melbourne-based biotechnology established in 1997 to commercialize
research into Alzheimer's disease and other major age-related degenerative
disorders (Nasdaq: PRAN; ASX: PBT). Prana's technology was discovered by the
company's researchers at prominent international institutions including
Massachusetts General Hospital at Harvard Medical School, the University of
Melbourne and the Mental Health Research Institute in Melbourne. For more
information about Prana, please visit www.pranabio.com
This press release contains "forward looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995 regarding the Company's
business strategy and future plans of operation. Forward-looking statements
involve known and unknown risks and uncertainties; both general and specific to
the matters discussed in this press release. These and other important factors,
including those mentioned in various Securities and Exchange Commission filings
made by the Company, may cause the Company's actual results and performance to
differ materially from the future results and performance expressed in or
implied by such forward-looking statements. The forward-looking statements
contained in this press release speak only as of the date hereof and the Company
expressly disclaims any obligation to provide public updates, revisions or
amendments to any forward-looking statements made herein to reflect changes in
the Company's expectations or future events.
SOURCE Prana Biotechnology Limited
Ich sehe, dass prana seinen Weg machen wird!
Nach den Presentationen, werden noch mehr Fonds einsteigen!
(Printer friendly version) Prana's Founding Scientist to Present at Banc of America 2004 Healthcare Conference
MELBOURNE, Australia, May 11, 2004 /PRNewswire-FirstCall via COMTEX/ -- Prana
Biotechnology Limited (Nasdaq: PRAN, ASX: PBT) today announced that its founding
scientist Dr. Ashley Bush, of Harvard Medical School, will present at the Banc
of America 2004 Healthcare Conference at The Four Seasons Hotel in Las Vegas on
Thursday, May 20th, 2004, at 8:00 AM PDT.
Dr. Bush's theories concerning the interaction between metals and the protein
beta-amyloid in the brain are the basis of Prana's treatments for Alzheimer's
and other neurodegenerative diseases.
The conference will include both a company presentation and a moderated
discussion between management and institutional investors.
To arrange a one-on-one meeting with Dr. Bush during the conference, please
contact Steven Silver at The Anne McBride Company, tel. 212-983-1702, ext 212,
or silver@annemcbride.com.
About Prana
Prana is a Melbourne-based biotechnology established in 1997 to commercialize
research into Alzheimer's disease and other major age-related degenerative
disorders (Nasdaq: PRAN; ASX: PBT). Prana's technology was discovered by the
company's researchers at prominent international institutions including
Massachusetts General Hospital at Harvard Medical School, the University of
Melbourne and the Mental Health Research Institute in Melbourne. For more
information about Prana, please visit www.pranabio.com
This press release contains "forward looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995 regarding the Company's
business strategy and future plans of operation. Forward-looking statements
involve known and unknown risks and uncertainties; both general and specific to
the matters discussed in this press release. These and other important factors,
including those mentioned in various Securities and Exchange Commission filings
made by the Company, may cause the Company's actual results and performance to
differ materially from the future results and performance expressed in or
implied by such forward-looking statements. The forward-looking statements
contained in this press release speak only as of the date hereof and the Company
expressly disclaims any obligation to provide public updates, revisions or
amendments to any forward-looking statements made herein to reflect changes in
the Company's expectations or future events.
SOURCE Prana Biotechnology Limited
Ich sehe, dass prana seinen Weg machen wird!
Nach den Presentationen, werden noch mehr Fonds einsteigen!
15.06.04 11:54
#31
geldschneider
Die Kapitalerhöung drückt auf den Kurs
Latest News
--------------------------------------------------
(Printer friendly version) Prana Biotechnology $US20m capital raising goes ahead
Sydney, Jun 02, 2004 (RWE via COMTEX) -- Shareholders in Prana Biotechnology
Ltd have approved the issue of securities worth $US20 million to institutional
and professional investors, led by New York-based healthcare fund managers
OrbiMed Advisors and XMark Funds.
The transaction was originally announced on April 28.
Prana executive chairman Mr Geoffrey Kempler commented: "This substantial
support shown by leaders in the healthcare investment community reflects the
progress and strength of Prana's technology.
"With this offering, we have been able to enhance shareholder value by
increasing our access and exposure to the vast US capital markets and broaden
our base of US institutional investors, complementing our traditional Australian
shareholder base."
"This capital raising will provide the funds to progress PBT-2, our proprietary
MPAC for Alzheimer's disease, into clinical trials in Australia through 2005 and
2006," said Mr Kempler.
Investors also bought five-year warrants to purchase an additional 3 million
ADRs at an exercise price of $US8 per ADR.
If exercised, this would raise an additional $US24 million for the company.
Prana shares today rose 3c to 68c.
RWE Australian Business News
URL: rweabn.com.au
Copyright 2004 RWEABN
SUBJECT CODE: Australian Equities
DJIA 10,334.70 75.40
Nasdaq 1,969.99 29.88
S&P 500 1,125.29 11.18
30 Yr Bond 5.53 0.06
10 Yr Bond 4.87 0.08
$7 Trades, Fast Executions & Real-Time Balances. Go!
Keyword Search
Enter Keyword
--------------------------------------------------
Exchange market data provided by DTN Market Access. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither FreeRealTime.com nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the FreeRealTime.com site, a member has agreed to the FreeRealTime.com Member Agreement.
Copyright © 1998-2004 FreeRealTime.com, Inc. All rights reserved.
User Agreement, Privacy Statement, Version 3.50
In Australien heute unverändert bei 0,7 das sind o,48 us $
Nachbörslich in USA gestern bei 4,71 (x 10)
gruß
gs
--------------------------------------------------
(Printer friendly version) Prana Biotechnology $US20m capital raising goes ahead
Sydney, Jun 02, 2004 (RWE via COMTEX) -- Shareholders in Prana Biotechnology
Ltd have approved the issue of securities worth $US20 million to institutional
and professional investors, led by New York-based healthcare fund managers
OrbiMed Advisors and XMark Funds.
The transaction was originally announced on April 28.
Prana executive chairman Mr Geoffrey Kempler commented: "This substantial
support shown by leaders in the healthcare investment community reflects the
progress and strength of Prana's technology.
"With this offering, we have been able to enhance shareholder value by
increasing our access and exposure to the vast US capital markets and broaden
our base of US institutional investors, complementing our traditional Australian
shareholder base."
"This capital raising will provide the funds to progress PBT-2, our proprietary
MPAC for Alzheimer's disease, into clinical trials in Australia through 2005 and
2006," said Mr Kempler.
Investors also bought five-year warrants to purchase an additional 3 million
ADRs at an exercise price of $US8 per ADR.
If exercised, this would raise an additional $US24 million for the company.
Prana shares today rose 3c to 68c.
RWE Australian Business News
URL: rweabn.com.au
Copyright 2004 RWEABN
SUBJECT CODE: Australian Equities
DJIA 10,334.70 75.40
Nasdaq 1,969.99 29.88
S&P 500 1,125.29 11.18
30 Yr Bond 5.53 0.06
10 Yr Bond 4.87 0.08
$7 Trades, Fast Executions & Real-Time Balances. Go!
Keyword Search
Enter Keyword
--------------------------------------------------
Exchange market data provided by DTN Market Access. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither FreeRealTime.com nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the FreeRealTime.com site, a member has agreed to the FreeRealTime.com Member Agreement.
Copyright © 1998-2004 FreeRealTime.com, Inc. All rights reserved.
User Agreement, Privacy Statement, Version 3.50
In Australien heute unverändert bei 0,7 das sind o,48 us $
Nachbörslich in USA gestern bei 4,71 (x 10)
gruß
gs
10.08.04 13:00
#32
geldschneider
Prana hat die Patentrechte für USA und Japan
Prana settles patents dispute
Sydney, Aug 09, 2004 (RWE via COMTEX) -- Prana Biotechnology Ltd says it andMassachusetts General Hospital have agreed to settle all outstanding litigationwith PN Gerolymatos SA (PNG) regarding the exploitation rights to certainpatents relating to pharmaceutical compositions and uses of clioquinol (alsoknown as PBT-1).Accordingly, all patent oppositions in Europe and Austra lia are being withdrawnand the law suits pending before the US District Court for the District ofColumbia and the Court of Athens in Greece are being dismissed.As a result of the settlement, Prana and PNG have agreed to recognise the rightsof each other to develop clioquinol in their respective territories.Prana will hold the rights to clioquinol in the United States and Japan, whilePNG will hold the rights for European and other territories.RWE Australian Business NewsURL: rweabn.com.auCopyright 2004 RWEABNSUBJECT CODE: Australian EquitiesPRANA BIOTECHNOLOGY LTD - Nasdaq SmallCap Market: PRAN
Chart Options 1 Day2 Day5 Day10 Day1 Month6 Month1 Year2 Year5 Year10 YearMax BarDotLineMountain 
Charts provided by Telescan
while
PNG will hold the rights for European and other territories.
Sydney, Aug 09, 2004 (RWE via COMTEX) -- Prana Biotechnology Ltd says it andMassachusetts General Hospital have agreed to settle all outstanding litigationwith PN Gerolymatos SA (PNG) regarding the exploitation rights to certainpatents relating to pharmaceutical compositions and uses of clioquinol (alsoknown as PBT-1).Accordingly, all patent oppositions in Europe and Austra lia are being withdrawnand the law suits pending before the US District Court for the District ofColumbia and the Court of Athens in Greece are being dismissed.As a result of the settlement, Prana and PNG have agreed to recognise the rightsof each other to develop clioquinol in their respective territories.Prana will hold the rights to clioquinol in the United States and Japan, whilePNG will hold the rights for European and other territories.RWE Australian Business NewsURL: rweabn.com.auCopyright 2004 RWEABNSUBJECT CODE: Australian EquitiesPRANA BIOTECHNOLOGY LTD - Nasdaq SmallCap Market: PRAN
Charts provided by Telescan
10.08.04 13:13
#33
geldschneider
Auf Forbes Liste: neurolog. drugs to watch!
| Prana Biotechnology Added To Forbes Neurological Drug Watch List |
MELBOURNE, Australia, Aug 9, 2004 /PRNewswire-FirstCall via COMTEX/ -- PranaBiotechnology Limited (Nasdaq: PRAN; ASX: PBT) today announced that Forbes.comhas once again added Prana to it's list of "neurological drugs to watch",highlighting the most promising experimental drugs to treat diseases of thebrain and nervous system.To obtain the web link of Forbes 'Neurological Drugs to Watch', please go to:http://www.forbes.com/sciencesandmedicine/2004/01/26/cx_mh_rl_neurotearsheet htmlAbout PranaPrana is a Melbourne-based biotechnology established in 1997 to commercializeresearch into Alzheimer's disease and other major age-related degenerativedisorders (Nasdaq: PRAN; ASX: PBT). Prana's technology was discovered by thecompany's researchers at prominent international institutions includingMassachusetts General Hospital at Harvard Medical School, the University ofMelbourne and the Mental Health Research Institute in Melbourne. For moreinformation about Prana, please visit http://www.pranabio.comThis press release contains "forward-looking statements" within the meaning ofthe Private Securities Litigation Reform Act of 1995 regarding the Company'sbusiness strategy and future plans of operation. Forward-looking statementsinvolve known and unknown risks and uncertainties; both general and specific tothe matters discussed in this press release. These and other important factors,including those mentioned in various Securities and Exchange Commission filingsmade by the Company, may cause the Company's actual results and performance todiffer materially from the future results and performance expressed in orimplied by such forward-looking statements. The forward-looking statementscontained in this press release speak only as of the date hereof and the Companyexpressly disclaims any obligation to provide public updates, revisions oramendments to any forward-looking statements made herein to reflect changes inthe Company's expectations or future events.SOURCE Prana Biotechnology LimitedCONTACT: Jonas Alsenas, CEO of Prana, +1-203-328-3097, jalsenas@pranabio.com; or Media Relations, Ivette Almeida, +1-212-983-1702, ext. 209, ivette.almeida@annemcbride.com; or Investor Relations, Rachel Levine, +1-212-983-1702, ext. 207, rlevine@annemcbride.comURL: http://www.pranabio.com http://www.prnewswire.comCopyright (C) 2004 PR Newswire. All rights reserved.KEYWORD: AustraliaINDUSTRY KEYWORD: MTC HEASUBJECT CODE: SVY |
10.08.04 13:47
#34
geldschneider
Prana erhält 1 % von PNG´s Einkommen bezügl.
des Verkaufes von PBT 1
Prana Settles Clioquinol Patent Litigation Conference Call To Be Hosted
MELBOURNE, Australia, Aug 9, 2004 (PRNewswire-FirstCall via COMTEX) -- Prana
Biotechnology Limited today announced that Prana and Massachusetts General
Hospital have agreed to settle all outstanding litigation with P.N Gerolymatos
S.A. (P.N.G.) regarding the exploitation rights to certain patents relating to
pharmaceutical compositions and uses of clioquinol (also known as PBT-1).
Accordingly, all patent oppositions in Europe and Australia are being withdrawn
and the law suits pending before the U.S. District Court for the District of
Columbia and the Court of Athens in Greece are being dismissed.
As a result of the settlement, Prana and P.N.G. have agreed to recognize the
rights of each other to develop clioquinol in their respective territories.
Prana will hold the rights to clioquinol in the United States and Japan, while
P.N.G. will hold the rights for European and other territories. Prana has agreed
to allot 1.35 million shares which will be held in escrow for twelve months and
pay a royalty to P.N.G. on sales in the USA and Japan, Prana will receive a
percentage of PNG's income for the other territories.
Mr. Geoffrey Kempler, Executive Chairman of Prana commented, "Prana now holds
issued patents in the US on clioquinol (PBT-1), a drug which has already
demonstrated that it can slow down the progression of the disease in a group of
moderate to severe Alzheimer's disease patients. In December 2003, promising
Phase II clinical trial results evaluating clioquinol in Alzheimer's disease
were published in the Archives of Neurology. This settlement heralds a very
important opportunity for Prana, its an important part of our drug pipeline and
allows Prana to undertake further clinical development of clioquinol."
"Furthermore, the assignment of these patents also complements the position of
our newer drugs, including PBT-2, which is now in the final months of toxicology
testing before entering Phase 1 clinical trials," said Mr. Kempler.
Commenting on the settlement, Mr. Panayotis Gerolymatos, President and Chief
Executive Officer of P.N. Gerolymatos S.A. stated: "We are pleased to put this
litigation behind us. The amicable settlement makes possible the further
development of clioquinol and we look forward to working jointly with Prana in
this regard."
Unlike current approved Alzheimer's therapies that largely treat the symptoms of
the disease, clioquinol, PBT-2 and Prana's other MPAC's (Metal Protein
Attenuating Compound) hold promise to help prevent the progression of the
disease.
The Company will conduct a teleconference to discuss the patent litigation,
Monday, August 9th, at 5:00 PM US Eastern Time or Tuesday, August 10th at 7 AM
Australian Eastern Time. To participate in the call, please dial 1-800-792-0846
from the US or Canada (toll free), or +1-800-002-092 from Australia, or
+1-706-634-1485 from other locations approximately 5 minutes prior to the
starting time. A replay of the call will be available from 5:45pm ET on Monday,
August 9, 2004, until 11:59pm ET on Tuesday, August 16. To
access the replay, please dial 1-800-642-1687, or +1-706-645-9291 from Australia
or other locations.
Webcast will be available at http://www.pranabio.com/
About Prana Biotechnology Limited
Prana Biotechnology was established to commercialize research into Alzheimer's
disease and other major age-related degenerative disorders. The company was
incorporated in 1997 and listed on the Australian Stock Exchange in March 2000
and listed on NASDAQ in September 2002. Researchers at prominent international
institutions including the University of Melbourne and Massachusetts General
Hospital as a teaching hospital of Harvard Medical School discovered Prana's
technology.
This press release contains "forward looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995 regarding the Company's
business strategy and future plans of operation. Forward-looking statements
involve known and unknown risks and uncertainties; both general and specific to
the matters discussed in this press release. These and other important factors,
including those mentioned in various Securities and Exchange Commission filings
made by the Company, may cause the Company's actual results and performance to
differ materially from the future results and performance expressed in or
implied by such forward-looking statements. The forward-looking statements
contained in this press release speak only as of the date hereof and the Company
expressly disclaims any obligation to provide public updates, revisions or
amendments to any forward-looking statements made herein to reflect changes in
the Company's expectations or future events.
For further information, please visit our web site at http://www.pranabio.com/.
SOURCE Prana Biotechnology Limited
CONTACT: Dianne Angus, Prana Biotechnology Ltd., +61-3-9349-4906; or Ivette Almeida, Media Relations, +1-212-983-1702 ext. 209, or Rachel Levine, Investor Relations, +1-212-983-1702 ext. 207, for Prana Biotechnology Limited; or Donita Boddie, Massachusetts General Hospital, +1-617-724-5627
URL: http://www.pranabio.com/
http://www.prnewswire.com
Copyright (C) 2004 PR Newswire. All rights reserved.
KEYWORD: Australia
Massachusetts
INDUSTRY KEYWORD: HEA
BIO
MTC
SUBJECT CODE: LAW
CCA
02.09.04 17:16
#35
geldschneider
ausführliche Analyse
VectorVest Stock Analysis of Prana BiotchADR as of 9/1/2004
Thank you for requesting an analysis of Prana BiotchADR from VectorVest. The ticker symbol for Prana BiotchADR is PRAN. PRAN is traded on the NASDAQ - (O)
Analysis Summary
PRAN is overvalued compared to its Price of $3.90 per share, has somewhat below average safety, and is currently rated a Hold.
In-Depth Analysis
Business: PRANA BIOTECHNOLOGY LTD -ADR, (PRAN) Seeks to commercialize research into Alzheimer's disease and other major age-related degenerative disorders. The company's mission is to develop diagnostic and therapeutic drugs to treat the central disease pathways that cause degeneration of the brain
Price: PRAN closed on 9/1/2004 at $3.90 per share
Value: Value is a measure of a stock's current worth. PRAN has a current Value of $1.05 per share. Therefore, it is overvalued compared to its Price of $3.90 per share. Value is computed from forecasted earnings per share, forecasted earnings growth, profitability, interest, and inflation rates. Value increases when earnings, earnings growth rate and profitably increase, and when interest and inflation rates decrease. VectorVest advocates the purchase of undervalued stocks. At some point in time, a stock's Price and Value always will converge.
RV (Relative Value): RV is an indicator of long-term price appreciation potential. PRAN has an RV of 0.32, which is very poor on a scale of 0.00 to 2.00. This indicator is far superior to a simple comparison of Price and Value because it is computed from an analysis of projected price appreciation three years out, AAA Corporate Bond Rates, and risk. RV solves the riddle of whether it is preferable to buy High growth, High P/E stocks, or Low growth, Low P/E stocks. VectorVest favors the purchase of stocks with RV ratings above 1.00.
RS (Relative Safety): RS is an indicator of risk. PRAN has an RS rating of 0.85, which is fair on a scale of 0.00 to 2.00. RS is computed from an analysis of the consistency and predictability of a company's financial performance, debt to equity ratio, sales volume, business longevity, price volatility and other factors. A stock with an RS rating greater than 1.00 is safer and more predictable than the average stock in the VectorVest database. VectorVest favors the purchase of stocks of companies with consistent, predictable financial performance.
RT (Relative Timing): RT is a fast, smart, accurate indicator of a stock's price trend. PRAN has a Relative Timing rating of 0.73, which is poor on a scale of 0.00 to 2.00. RT is computed from an analysis of the direction, magnitude, and dynamics of a stock's price movements over one day, one week, one quarter and one year time periods. Once a stock's price has established a strong trend, it is expected to continue in that trend for the short-term. If a trend dissipates, RT will gravitate toward 1.00. RT will explode from bottoms, dive from tops, and reflect changes in price momentum. VectorVest favors the purchase of stocks with RT ratings above 1.00.
VST (VST-Vector): VST is the master indicator for ranking every stock in the VectorVest database. PRAN has a VST rating of 0.69, which is poor on a scale of 0.00 to 2.00. VST is computed from the square root of a weighted sum of the squares of RV, RS, and RT. Stocks with the highest VST ratings have the best combinations of Value, Safety and Timing. These are the stocks to own for above average, long-term capital appreciation. VectorVest advocates the purchase of safe, undervalued stocks rising in price. The efficacy of this indicator was demonstrated in a study conducted at the University of Chicago which showed that high VST stocks outperformed the S&P 500 by 583.1% over the six year period from 1996 through 2002.
CI (Comfort Index): CI is an indicator which reflects a stock's ability to resist severe and/or lengthy price declines. PRAN has a CI rating of 1.11, which is good on a scale of 0.00 to 2.00. CI is quite different from RS in that it is based solely upon a stock's long-term price history. VectorVest advocates the purchase of high CI stocks.
GRT (Earnings Growth Rate): GRT reflects a company's one to three year forecasted earnings growth rate in percent per year. PRAN has a forcasted Earnings Growth Rate of -7.00%, which VectorVest considers to be very poor. GRT is computed from historical, current and forecasted earnings data. It is updated each week for every stock in the VectorVest database. GRT often foretells a stock's future price trend. If a stock's GRT trend is upward, the stock's price will likely rise. If GRT is trending downward, the stock's Price will probably fall. VectorVest favors the purchase of stocks whose GRT is rising and is greater than the sum of current inflation and interest rates, (8.72%).
Recommendation (REC): VectorVest gives a Buy, Sell, Hold recommendation on every stock, every day. PRAN has a Hold recommendation. REC reflects the cumulative effect of all the VectorVest parameters working together. These parameters are designed to help investors buy safe, undervalued stocks rising in price. They also help investors avoid or sell risky, overvalued stocks falling in price. VectorVest recommends that investors buy high VST-Vector, Buy-rated stocks in rising markets.
Stop (Stop-Price): Stop is an indicator of when to sell a long position or cover a short position. PRAN has a Stop of $3.83 per share. This is $0.07 below PRAN's current closing Price. A stock's Stop is computed from a 13 week moving average of its closing prices, and is fine-tuned according to the stock's fundamentals. High RV, high RS stocks have lower Stops, and low RV, low RS stocks have higher Stops. In the VectorVest system, a stock gets a 'B' or 'H' recommendation if its Price is above its Stop and an 'S' recommendation if its Price is below its Stop.
EPS (Earnings per Share): EPS stands for leading 12 months Earnings Per Share. PRAN has a forecasted EPS of $-1.22 per share. VectorVest determines this forecast from a combination of recent earnings performance and traditional fiscal and/or calendar year earnings forecasts.
P/E (Price to Earnings Ratio): P/E is a popular measure of stock valuation which shows the dollars required to buy one dollar of earnings. PRAN has a P/E of -3.20. This ratio may be deemed to be high or low depending upon your frame of reference. The average P/E of all the stocks in the VectorVest database is 27.54. P/E is computed daily using the formula: P/E = Price/EPS.
EY (Earnings Yield): EY reflects earnings per share as a percent of Price. EY is related to P/E via the formula, EY = 100 / (P/E), and may be used in place of P/E as a measure of valuation. EY has the advantages that it is always determinate and can reflect negative earnings. PRAN has an EY of -31.27 percent. This is below the current average of 3.64% for all the stocks in the VectorVest database. EY equals 100 x (EPS/Price).
GPE (Growth to P/E Ratio): GPE is another popular measure of stock valuation. It compares earnings growth rate to P/E ratio. PRAN has a GPE rating of -2.19. High growth stocks are believed to be able to justify high P/E ratios. A stock is commonly considered to be undervalued when GPE is greater than 1.00 and overvalued when GPE is below 1.00. Unfortunately, this rule of thumb does not take into account the effect of interest rates on P/E ratios. The operative GPE ratio of 1.00 is valid when and only when interest rates equal 10%. With long-term interest rates currently at 5.72%, the operative GPE ratio is 0.33. Therefore, PRAN may be considered to be overvalued.
DIV (Dividend): VectorVest reports annual, regular, cash dividends as indicated by the most recent payments. Special distributions, one-time payments, stock dividends, etc., are not generally included in DIV. PRAN does not pay a dividend.
DY (Dividend Yield): DY reflects earnings per share as a percent of Price. PRAN does not pay a dividend, so it does not have a Dividend Yield rating. . DY equals 100 x (DIV/Price). It is useful to compare DY with EY. If DY is not significantly lower than EY, the dividend payment may be in jeopardy.
DS (Dividend Safety): DS is an indicator of the assurance that regular cash dividends will be declared and paid at current or at higher rates for the foreseeable future. PRAN does not pay a dividend, so it does not have a Dividend Safety rating . Stocks with DS values above 75 typically have RS values well above 1.00 and EY levels that are much higher than DY.
DG (Dividend Growth Rate): Dividend Growth is a subtle yet important indicator of a company's financial performance. It also provides some insight into the board's outlook on the company's ability to increase earnings. PRAN does not pay a dividend, so it does not have a Dividend Growth rating .
YSG (YSG-Vector): YSG is an indicator which combines DIV, DY and DG into a single value, and allows direct comparison of all dividend-paying stocks in the database. PRAN does not pay a dividend, so it does not have a YSG rating . Stocks with the highest YSG values have the best combinations of Dividend Yield, Safety and Growth. These are the stocks to buy for above average current income and long-term growth.
Open: PRAN opened trading at a price of $4.02 per share on 9/1/2004.
High: PRAN traded at a High price of $4.05 per share on 9/1/2004.
Low: PRAN traded at a Low price of $3.84 per share on 9/1/2004
Close: PRAN closed trading at price $3.90 per share on 9/1/2004. (Close is also called Price in the VectorVest system)
Range: Range reflects the difference between the High and Low prices for the day. PRAN traded with a range of $0.21 per share on 9/1/2004.
$Change: PRAN closed down 0.10 from the prior day's closing Price.
%PRC: PRAN's Price changed -2.50% from the prior day's closing price.
Volume: PRAN traded 7,300 shares on 9/1/2004.
AvgVol: AvgVol is the 50 day moving average of daily volume as computed by VectorVest. PRAN has an AvgVol of 59,800 shares traded per day.
%Vol: %Vol reflects the percent change in today's trading volume as compared to the AvgVol. %Vol equals 100 x (Volume/AvgVol). PRAN had a %Vol of -87.79% on 9/1/2004
Sales: PRAN has annual sales of $1,000,000
Sales Growth: Sales Growth is the Sales Growth Rate in percent over the last 12 months. PRAN has a Sales Growth of 177.00% per year. This is excellent. Sales Growth is updated each week for every stock. It is often useful to compare Sales Growth to Earnings Growth to gain an insight into a company's operations.
Sales Per Share (SPS): PRAN has annual sales of $0.17 per share. SPS can be used as a measure of valuation when comparing stocks within an Industry Group.
Price to Sales Ratio (P/S): PRAN has a P/S of 22.45. This ratio is also used as a measure of valuation. Here, too, it is useful when comparing stocks within an Industry Group.
Shares: PRAN has 6,000,000 shares of stock outstanding.
Market Capitalization: PRAN has a Market Capitalization of $25,000,000. Market Capitalization is calculated by multiplying price times shares outstanding.
Industry Group: PRAN has been assigned to the Drug (Biomedical\Genetic) Industry Group. VectorVest classifies stocks into over 200 Industry Groups and 40 Business Sectors.
Business Sector: PRAN has been assigned to the Drug Business Sector. VectorVest classifies stocks into over 200 Industry Groups and 40 Business Sectors.
The basic strategy of VectorVest is to buy Low risk, High reward stocks. We suggest that Prudent investors buy enough High Relative Value, High Relative Safety stocks to keep the overall RV and RS ratings of their portfolios above 1.00. As you do this, you'll find that your risk will go down and your investment performance will improve.
Graph
Prana BiotchADR
Drug (Biomedical\Genetic)
For more information, please click here.
Thank you for requesting an analysis of Prana BiotchADR from VectorVest. The ticker symbol for Prana BiotchADR is PRAN. PRAN is traded on the NASDAQ - (O)
Analysis Summary
PRAN is overvalued compared to its Price of $3.90 per share, has somewhat below average safety, and is currently rated a Hold.
In-Depth Analysis
Business: PRANA BIOTECHNOLOGY LTD -ADR, (PRAN) Seeks to commercialize research into Alzheimer's disease and other major age-related degenerative disorders. The company's mission is to develop diagnostic and therapeutic drugs to treat the central disease pathways that cause degeneration of the brain
Price: PRAN closed on 9/1/2004 at $3.90 per share
Value: Value is a measure of a stock's current worth. PRAN has a current Value of $1.05 per share. Therefore, it is overvalued compared to its Price of $3.90 per share. Value is computed from forecasted earnings per share, forecasted earnings growth, profitability, interest, and inflation rates. Value increases when earnings, earnings growth rate and profitably increase, and when interest and inflation rates decrease. VectorVest advocates the purchase of undervalued stocks. At some point in time, a stock's Price and Value always will converge.
RV (Relative Value): RV is an indicator of long-term price appreciation potential. PRAN has an RV of 0.32, which is very poor on a scale of 0.00 to 2.00. This indicator is far superior to a simple comparison of Price and Value because it is computed from an analysis of projected price appreciation three years out, AAA Corporate Bond Rates, and risk. RV solves the riddle of whether it is preferable to buy High growth, High P/E stocks, or Low growth, Low P/E stocks. VectorVest favors the purchase of stocks with RV ratings above 1.00.
RS (Relative Safety): RS is an indicator of risk. PRAN has an RS rating of 0.85, which is fair on a scale of 0.00 to 2.00. RS is computed from an analysis of the consistency and predictability of a company's financial performance, debt to equity ratio, sales volume, business longevity, price volatility and other factors. A stock with an RS rating greater than 1.00 is safer and more predictable than the average stock in the VectorVest database. VectorVest favors the purchase of stocks of companies with consistent, predictable financial performance.
RT (Relative Timing): RT is a fast, smart, accurate indicator of a stock's price trend. PRAN has a Relative Timing rating of 0.73, which is poor on a scale of 0.00 to 2.00. RT is computed from an analysis of the direction, magnitude, and dynamics of a stock's price movements over one day, one week, one quarter and one year time periods. Once a stock's price has established a strong trend, it is expected to continue in that trend for the short-term. If a trend dissipates, RT will gravitate toward 1.00. RT will explode from bottoms, dive from tops, and reflect changes in price momentum. VectorVest favors the purchase of stocks with RT ratings above 1.00.
VST (VST-Vector): VST is the master indicator for ranking every stock in the VectorVest database. PRAN has a VST rating of 0.69, which is poor on a scale of 0.00 to 2.00. VST is computed from the square root of a weighted sum of the squares of RV, RS, and RT. Stocks with the highest VST ratings have the best combinations of Value, Safety and Timing. These are the stocks to own for above average, long-term capital appreciation. VectorVest advocates the purchase of safe, undervalued stocks rising in price. The efficacy of this indicator was demonstrated in a study conducted at the University of Chicago which showed that high VST stocks outperformed the S&P 500 by 583.1% over the six year period from 1996 through 2002.
CI (Comfort Index): CI is an indicator which reflects a stock's ability to resist severe and/or lengthy price declines. PRAN has a CI rating of 1.11, which is good on a scale of 0.00 to 2.00. CI is quite different from RS in that it is based solely upon a stock's long-term price history. VectorVest advocates the purchase of high CI stocks.
GRT (Earnings Growth Rate): GRT reflects a company's one to three year forecasted earnings growth rate in percent per year. PRAN has a forcasted Earnings Growth Rate of -7.00%, which VectorVest considers to be very poor. GRT is computed from historical, current and forecasted earnings data. It is updated each week for every stock in the VectorVest database. GRT often foretells a stock's future price trend. If a stock's GRT trend is upward, the stock's price will likely rise. If GRT is trending downward, the stock's Price will probably fall. VectorVest favors the purchase of stocks whose GRT is rising and is greater than the sum of current inflation and interest rates, (8.72%).
Recommendation (REC): VectorVest gives a Buy, Sell, Hold recommendation on every stock, every day. PRAN has a Hold recommendation. REC reflects the cumulative effect of all the VectorVest parameters working together. These parameters are designed to help investors buy safe, undervalued stocks rising in price. They also help investors avoid or sell risky, overvalued stocks falling in price. VectorVest recommends that investors buy high VST-Vector, Buy-rated stocks in rising markets.
Stop (Stop-Price): Stop is an indicator of when to sell a long position or cover a short position. PRAN has a Stop of $3.83 per share. This is $0.07 below PRAN's current closing Price. A stock's Stop is computed from a 13 week moving average of its closing prices, and is fine-tuned according to the stock's fundamentals. High RV, high RS stocks have lower Stops, and low RV, low RS stocks have higher Stops. In the VectorVest system, a stock gets a 'B' or 'H' recommendation if its Price is above its Stop and an 'S' recommendation if its Price is below its Stop.
EPS (Earnings per Share): EPS stands for leading 12 months Earnings Per Share. PRAN has a forecasted EPS of $-1.22 per share. VectorVest determines this forecast from a combination of recent earnings performance and traditional fiscal and/or calendar year earnings forecasts.
P/E (Price to Earnings Ratio): P/E is a popular measure of stock valuation which shows the dollars required to buy one dollar of earnings. PRAN has a P/E of -3.20. This ratio may be deemed to be high or low depending upon your frame of reference. The average P/E of all the stocks in the VectorVest database is 27.54. P/E is computed daily using the formula: P/E = Price/EPS.
EY (Earnings Yield): EY reflects earnings per share as a percent of Price. EY is related to P/E via the formula, EY = 100 / (P/E), and may be used in place of P/E as a measure of valuation. EY has the advantages that it is always determinate and can reflect negative earnings. PRAN has an EY of -31.27 percent. This is below the current average of 3.64% for all the stocks in the VectorVest database. EY equals 100 x (EPS/Price).
GPE (Growth to P/E Ratio): GPE is another popular measure of stock valuation. It compares earnings growth rate to P/E ratio. PRAN has a GPE rating of -2.19. High growth stocks are believed to be able to justify high P/E ratios. A stock is commonly considered to be undervalued when GPE is greater than 1.00 and overvalued when GPE is below 1.00. Unfortunately, this rule of thumb does not take into account the effect of interest rates on P/E ratios. The operative GPE ratio of 1.00 is valid when and only when interest rates equal 10%. With long-term interest rates currently at 5.72%, the operative GPE ratio is 0.33. Therefore, PRAN may be considered to be overvalued.
DIV (Dividend): VectorVest reports annual, regular, cash dividends as indicated by the most recent payments. Special distributions, one-time payments, stock dividends, etc., are not generally included in DIV. PRAN does not pay a dividend.
DY (Dividend Yield): DY reflects earnings per share as a percent of Price. PRAN does not pay a dividend, so it does not have a Dividend Yield rating. . DY equals 100 x (DIV/Price). It is useful to compare DY with EY. If DY is not significantly lower than EY, the dividend payment may be in jeopardy.
DS (Dividend Safety): DS is an indicator of the assurance that regular cash dividends will be declared and paid at current or at higher rates for the foreseeable future. PRAN does not pay a dividend, so it does not have a Dividend Safety rating . Stocks with DS values above 75 typically have RS values well above 1.00 and EY levels that are much higher than DY.
DG (Dividend Growth Rate): Dividend Growth is a subtle yet important indicator of a company's financial performance. It also provides some insight into the board's outlook on the company's ability to increase earnings. PRAN does not pay a dividend, so it does not have a Dividend Growth rating .
YSG (YSG-Vector): YSG is an indicator which combines DIV, DY and DG into a single value, and allows direct comparison of all dividend-paying stocks in the database. PRAN does not pay a dividend, so it does not have a YSG rating . Stocks with the highest YSG values have the best combinations of Dividend Yield, Safety and Growth. These are the stocks to buy for above average current income and long-term growth.
Open: PRAN opened trading at a price of $4.02 per share on 9/1/2004.
High: PRAN traded at a High price of $4.05 per share on 9/1/2004.
Low: PRAN traded at a Low price of $3.84 per share on 9/1/2004
Close: PRAN closed trading at price $3.90 per share on 9/1/2004. (Close is also called Price in the VectorVest system)
Range: Range reflects the difference between the High and Low prices for the day. PRAN traded with a range of $0.21 per share on 9/1/2004.
$Change: PRAN closed down 0.10 from the prior day's closing Price.
%PRC: PRAN's Price changed -2.50% from the prior day's closing price.
Volume: PRAN traded 7,300 shares on 9/1/2004.
AvgVol: AvgVol is the 50 day moving average of daily volume as computed by VectorVest. PRAN has an AvgVol of 59,800 shares traded per day.
%Vol: %Vol reflects the percent change in today's trading volume as compared to the AvgVol. %Vol equals 100 x (Volume/AvgVol). PRAN had a %Vol of -87.79% on 9/1/2004
Sales: PRAN has annual sales of $1,000,000
Sales Growth: Sales Growth is the Sales Growth Rate in percent over the last 12 months. PRAN has a Sales Growth of 177.00% per year. This is excellent. Sales Growth is updated each week for every stock. It is often useful to compare Sales Growth to Earnings Growth to gain an insight into a company's operations.
Sales Per Share (SPS): PRAN has annual sales of $0.17 per share. SPS can be used as a measure of valuation when comparing stocks within an Industry Group.
Price to Sales Ratio (P/S): PRAN has a P/S of 22.45. This ratio is also used as a measure of valuation. Here, too, it is useful when comparing stocks within an Industry Group.
Shares: PRAN has 6,000,000 shares of stock outstanding.
Market Capitalization: PRAN has a Market Capitalization of $25,000,000. Market Capitalization is calculated by multiplying price times shares outstanding.
Industry Group: PRAN has been assigned to the Drug (Biomedical\Genetic) Industry Group. VectorVest classifies stocks into over 200 Industry Groups and 40 Business Sectors.
Business Sector: PRAN has been assigned to the Drug Business Sector. VectorVest classifies stocks into over 200 Industry Groups and 40 Business Sectors.
The basic strategy of VectorVest is to buy Low risk, High reward stocks. We suggest that Prudent investors buy enough High Relative Value, High Relative Safety stocks to keep the overall RV and RS ratings of their portfolios above 1.00. As you do this, you'll find that your risk will go down and your investment performance will improve.
Graph
Prana BiotchADR
Drug (Biomedical\Genetic)
For more information, please click here.
02.09.04 17:18
#36
geldschneider
chartechnisch bildet sich ein W
Derzeit in richtung Spitze 2. Zacke, wird bis ca. 3,6 nach unten gehen und von da wieder nach oben, deshalb halten!
bzw. wer kann nachkaufen.
bzw. wer kann nachkaufen.
12.10.04 19:48
#39
geldschneider
Riesige Umsätze und News!
| Prana's Open Label Extension Study of PBT-1 Reinforces Positive Phase II Results - PBT-1 Slows Alzheimer's Disease Progression and Well Tolerated by Patients - |
MELBOURNE, Australia, Oct 12, 2004 /PRNewswire-FirstCall via COMTEX/ -- PranaBiotechnology Limited (Nasdaq: PRAN, ASX: PBT), today announced the results ofthe open label 84-week "Extension Study" of its Phase II clinical trial of PBT-1(clioquinol) study, also known as the CQAD study. The data from the formaltreatment phase of the study was published in the December 2003 issue ofArchives of Neurology.All participants from the original 36-week blinded and placebo-controlledportion of the Phase II trial were offered the opportunity to continue the PBT-1treatment on an open label basis for an additional 48 weeks. 18 (66.7%) out of27 patients elected to start the CQADEX extension study. Nine patients completedthe full 84-week study."The Extension Study data demonstrates that PBT-1 treatment for Alzheimer'sappears to slow the expected disease progression by about half," said JonAlsenas, DVM, chief executive officer of Prana Biotechnology Limited. "The rateof decline in PBT-1 treated patients, compared to the predicted rate of decline,suggests that the drug has a disease-modifying treatment effect, not simply acognition enhancement effect. Moreover, the results show that PBT-1 is welltolerated by patients and has no increased adverse effects over those to beexpected in untreated patients suffering from Alzheimer's disease."Data from the Extension Study data revealed that Alzheimer's patients withADAS-cog scores similar to those in the CQAD and the CQADEX would have beenexpected to decline by an average of 18 points over the treatment period. Theresults showed an average decline of approximately eight points for a differenceof 10 points from that predicted without treatment in the nine patients on PBT-1for 84 weeks. Results from the MMSE (Mini Mental State Examination) were alsoencouraging, as, when compared to baseline, the patients on 84 weeks of PBT-1demonstrated no statistically significant decline."PBT-1 represents a novel approach to Alzheimer's: namely, a disease-modifier.In other words, PBT-1 targets a key feature of the underlying process thatappears to cause the destruction of nerve cells," said Sam Gandy, MD, PhD,Professor of Neurology and Director of the Farber Institute at Thomas JeffersonUniversity. "Alzheimer's is believed to begin as long as 10 years or more beforeclinical memory loss is manifested. Accordingly, disease-modifying drugs mayneed to be administered for many years. Along this line, it is extremelyencouraging to see evidence that PBT-1 is well-tolerated for extended periods."The full publication on the data from the extension study is available onPrana's website http://www.pranabio.com.Prana is currently evaluating the next potential steps in continued PBT-1clinical development and anticipates being able to announce its plans in thenear future.Company Management is hosting an Analyst Day at The Four Seasons, Salon A&B, inNew York City, on Monday, October 18, 2004. Featured speakers will include Dr.Bush, Professor Rudolph Tanzi, Neurology, Harvard Medical School, MassachusettsGeneral Hospital, Dr. Craig William Ritchie, Psychiatry, Royal Free Campus,University College London, UK and Medical Director, Clinical Trials Centre, UCLBiomedica, University College London, UK, as well as Dr. Jon Alsenas, CEO andDr. Ross Murdoch, COO of Prana.About Prana Biotechnology LimitedPrana Biotechnology was established to commercialize research into Alzheimer'sdisease and other major age-related degenerative disorders. The company wasincorporated in 1997 and listed on the Australian Stock Exchange in March 2000and listed on NASDAQ in September 2002. Researchers at prominent internationalinstitutions including the University of Melbourne and Massachusetts GeneralHospital, a teaching hospital of Harvard Medical School, discovered Prana'stechnology.This press release contains "forward looking statements" within the meaning ofthe Private Securities Litigation Reform Act of 1995 regarding the Company'sbusiness strategy and future plans of operation. Forward-looking statementsinvolve known and unknown risks and uncertainties; both general and specific tothe matters discussed in this press release. These and other important factors,including those mentioned in various Securities and Exchange Commission filingsmade by the Company, may cause the Company's actual results and performance todiffer materially from the future results and performance expressed in orimplied by such forward-looking statements. The forward-looking statementscontained in this press release speak only as of the date hereof and the Companyexpressly disclaims any obligation to provide public updates, revisions oramendments to any forward-looking statements made herein to reflect changes inthe Company's expectations or future events.For further information, please visit our web site at http://www.pranabio.com.SOURCE Prana Biotechnology LimitedCONTACT: Jon Alsenas, CEO of Prana Biotechnology Ltd., +1-203-328-3097; or Media, Ivette Almeida, +1-212-983-1702 ext. 209, or Investors, Rachel Levine, +1-212-983-1702 ext. 207, both for Prana Biotechnology Ltd. URL: http://www.pranabio.com http://www.prnewswire.comCopyright (C) 2004 PR Newswire. All rights reserved.KEYWORD: AustraliaINDUSTRY KEYWORD: HEA MTC BIOSUBJECT CODE: SVY CCA |
12.10.04 20:06
#40
geldschneider
100 % buy
| Composite Indicator | ||||||||||||
| Trend Spotter TM | Buy | |||||||||||
| Short Term Indicators | ||||||||||||
| 7 Day Average Directional Indicator | Buy | |||||||||||
| 10 - 8 Day Moving Average Hilo Channel | Buy | |||||||||||
| 20 Day Moving Average vs Price | Buy | |||||||||||
| 20 - 50 Day MACD Oscillator | Buy | |||||||||||
| 20 Day Bollinger Bands | Buy | |||||||||||
| Short Term Indicators Average: | 100% - Buy | |||||||||||
| 20-Day Average Volume - 24545 | ||||||||||||
| Medium Term Indicators | ||||||||||||
| 40 Day Commodity Channel Index | Buy | |||||||||||
| 50 Day Moving Average vs Price | Buy | |||||||||||
| 20 - 100 Day MACD Oscillator | Sell | |||||||||||
| 50 Day Parabolic Time/Price | Buy | |||||||||||
| Medium Term Indicators Average: | 50% - Buy | |||||||||||
| 50-Day Average Volume - 18112 | ||||||||||||
| Long Term Indicators | ||||||||||||
| 60 Day Commodity Channel Index | Buy | |||||||||||
| 100 Day Moving Average vs Price | Buy | |||||||||||
| 50 - 100 Day MACD Oscillator | Sell | |||||||||||
| Long Term Indicators Average: | 33% - Buy | |||||||||||
| 100-Day Average Volume - 42880 | ||||||||||||
| Overall Average: | 72% - Buy | |||||||||||
| ||||||||||||
| ||||||||||||
| PRAN | 4.76 |  0.17 (3.70) | 4.73 | 4.79 | 464,480 |
Antatt durchschnittlich 10`Tsd sind es nun 465`Tsd heute.
Da geht was!
12.10.04 20:15
#41
geldschneider
Klinische Studie I bringt das Interesse!
PRANA BIOTECHNOLOGY LTD - Nasdaq SmallCap Market: PRAN
Chart Options 1 Day2 Day5 Day10 Day1 Month6 Month1 Year2 Year5 Year10 YearMax BarDotLineMountain 
12.10.04 21:21
#43
geldschneider
Positve Resultate bei den klin. Studien erzielt
Associated Press
Prana: Extended Trial Results Positive
10.12.2004, 12:38 PM
Australian drug developer Prana Biotechnology Ltd. said Tuesday that an extended mid-stage trial of its PBT-1 Alzheimer's treatment demonstrated positive results, slowing the expected progression of the disease by about half.
Prana also said the extended Phase II trial showed the drug was well-tolerated by patients over a long period of time, an important factor for Alzheimer's patients who can expect drug regimens to last many years.
Nine patients from the original 27-patient, 36-week study completed an additional 48 weeks on the drug, for a total of 84 weeks on PBT-1.
The PBT-1 drug works by binding to zinc in the bloodstream, preventing the mineral's association with proteins that have been linked to Alzheimer's disease. Alzheimer's is a degenerative brain disease that affects about four million Americans, according to the National Institutes of Health.
Melbourne, Australia-based Prana concentrates its research on age-related diseases, focusing particularly on Alzheimer's as well as on cataracts and Parkinson's disease.
American depository receipts of Prana rose 16 cents, or 3.5 percent, to $4.75 in midday trading on the Nasdaq. The stock has stayed around $4 after hitting a 52-week high of $10.50 in April.
E-mail |-->Comments | E-Mail Newsletters | RSS
');//-->Today's Top Stories
Merrill Lynch Earnings Fall 8%
Associated Press - 10/12/04 9:46:08 AM ET
The company blames results on a slowdown in transactions prompted by an extremely slow summer on Wall Street.
Oil Prices Pass $54 Per Barrel
Associated Press - 10/12/04 10:00:07 AM ET
Crude for November delivery on the New York Mercantile Exchange reached a new high of $54.45, after settling overnight at $53.64.
quelle Forbes
News Headlines | More From Forbes.com | Special Reports
Prana: Extended Trial Results Positive
10.12.2004, 12:38 PM
Australian drug developer Prana Biotechnology Ltd. said Tuesday that an extended mid-stage trial of its PBT-1 Alzheimer's treatment demonstrated positive results, slowing the expected progression of the disease by about half.
Prana also said the extended Phase II trial showed the drug was well-tolerated by patients over a long period of time, an important factor for Alzheimer's patients who can expect drug regimens to last many years.
Nine patients from the original 27-patient, 36-week study completed an additional 48 weeks on the drug, for a total of 84 weeks on PBT-1.
The PBT-1 drug works by binding to zinc in the bloodstream, preventing the mineral's association with proteins that have been linked to Alzheimer's disease. Alzheimer's is a degenerative brain disease that affects about four million Americans, according to the National Institutes of Health.
Melbourne, Australia-based Prana concentrates its research on age-related diseases, focusing particularly on Alzheimer's as well as on cataracts and Parkinson's disease.
American depository receipts of Prana rose 16 cents, or 3.5 percent, to $4.75 in midday trading on the Nasdaq. The stock has stayed around $4 after hitting a 52-week high of $10.50 in April.
E-mail |-->Comments | E-Mail Newsletters | RSS
');//-->Today's Top Stories
Merrill Lynch Earnings Fall 8%
Associated Press - 10/12/04 9:46:08 AM ET
The company blames results on a slowdown in transactions prompted by an extremely slow summer on Wall Street.
Oil Prices Pass $54 Per Barrel
Associated Press - 10/12/04 10:00:07 AM ET
Crude for November delivery on the New York Mercantile Exchange reached a new high of $54.45, after settling overnight at $53.64.
quelle Forbes
12.10.04 21:24
#44
geldschneider
@bauwi, dann sollten wir unser Hirn noch
ausnutzen, solange es noch klar ist! Oder?
Ich hoffe für Prana und für die Alzheimerforschung, dass es einen Erfolg gibt.
gruß
geldschneider
14.10.04 00:24
#45
geldschneider
Institutionelle Beteiligungen
 | function relocate (form_object) { var v=form_object; if (v == 'symbol') { window.location.href="searchresults.cfm?getcompany=739727105&smethod=cusip&search=symbol&pt_flag=1"; } else if (v == 'mutual') { window.location.href="searchresults.cfm?getcompany=739727105&smethod=cusip&search=mutual&pt_flag=1"; } else if (v == 'edgar') { window.location.href="searchresults.cfm?getcompany=739727105&smethod=cusip&search=edgar&pt_flag=1"; } else if (v == 'insider') { window.location.href="searchresults.cfm?getcompany=739727105&smethod=cusip&search=insider&pt_flag=1"; } else if (v == 'combine') { window.location.href="searchresults.cfm?getcompany=739727105&smethod=cusip&search=combine&pt_flag=1"; } }
|
| Displaying North American Holders | |||
 | |||
| tablealiases.cfm template was included twice on this page. Please review your code and remove unnecessary procedures.--> | |||
|
recht interessant.
gruß
gsd
18.11.04 09:37
#46
geldschneider
Trend analyse
| Composite Indicator | ||||||||||||
| Trend Spotter TM | Buy | |||||||||||
| Short Term Indicators | ||||||||||||
| 7 Day Average Directional Indicator | Sell | |||||||||||
| 10 - 8 Day Moving Average Hilo Channel | Hold | |||||||||||
| 20 Day Moving Average vs Price | Buy | |||||||||||
| 20 - 50 Day MACD Oscillator | Buy | |||||||||||
| 20 Day Bollinger Bands | Hold | |||||||||||
| Short Term Indicators Average: | 20% - Buy | |||||||||||
| 20-Day Average Volume - 32155 | ||||||||||||
| Medium Term Indicators | ||||||||||||
| 40 Day Commodity Channel Index | Hold | |||||||||||
| 50 Day Moving Average vs Price | Buy | |||||||||||
| 20 - 100 Day MACD Oscillator | Buy | |||||||||||
| 50 Day Parabolic Time/Price | Buy | |||||||||||
| Medium Term Indicators Average: | 75% - Buy | |||||||||||
| 50-Day Average Volume - 54398 | ||||||||||||
| Long Term Indicators | ||||||||||||
| 60 Day Commodity Channel Index | Hold | |||||||||||
| 100 Day Moving Average vs Price | Buy | |||||||||||
| 50 - 100 Day MACD Oscillator | Buy | |||||||||||
| Long Term Indicators Average: | 67% - Buy | |||||||||||
| 100-Day Average Volume - 55703 | ||||||||||||
| Overall Average: | 56% - Buy | |||||||||||
| ||||||||||||
18.11.04 09:47
#47
geldschneider
BUY
|
| |||||||||||||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||||
18.11.04 09:51
#48
geldschneider
Hauptversammlung 17. Nov.
| Prana Biotechnology Announces Results of Annual General Meeting of Shareholders |
MELBOURNE, Australia, Nov 17, 2004 /PRNewswire-FirstCall via COMTEX/ -- PranaBiotechnology Limited (Nasdaq: PRAN, ASX: PBT), today announced the results ofits Annual General Meeting held on November 17, 2004. During the proceedings,the following resolutions were passed: -- Mr. Geoffrey Kempler was re-elected to serve as a director of the Company and Dr. Jonas Alsenas was elected to serve as a director of the Company; -- the approval of previous issuance of ordinary shares to P.N. Gerolymatos S.A. and to certain consultants of the Company pursuant to resolution of the patent dispute regarding PBT-1 that was announced in August; -- the adoption of the 2004 American Depositary Share (ADS) Option Plan and the 2004 Employees, Directors' and Consultants' Share and Option Plan, as well as the approval of up to an aggregate 12,000,000 ordinary shares or ADS issuable under the 2004 ADS Option Plan and the 2004 Employees, Directors' and Consultants' Share and Option Plan;"Prana Biotechnology made great strides in fiscal 2004," said Geoffrey Kempler,chairman. "Our most notable achievement was advancing from a pre- clinical stagecompany to a late-stage clinical company by securing the PBT-1 intellectualproperty and announcing the planned initiation of the PII/III PLACQUE study."Other achievements for 2004 included the announcement of results PBT-1 Phase IIExtension Study of Alzheimer's disease patients. According to Extension Studyresults released in October 2004, PBT-1 was well-tolerated in up to 84 weeks oftreatment in Alzheimer's patients. When compared to a historical control, PBT-1appeared to slow the rate of disease progression by approximately half.Prana announced a US$20 million placement of shares in April 2004 with leadingUS biotechnology investors led by OrbiMed Advisors and X Mark Funds andannounced the appointment of a US based CEO in August.Dr. Jon Alsenas, CEO added, "We are excited about the opportunities that lieahead for Prana in fiscal 2005. We will soon have two very promising Alzheimer'sdrugs in the clinic, with the PBT-1 Phase II/III study initiating in the latefirst quarter or the second quarter of 2005 and the PBT-2 Phase I clinical trialalso commencing in early 2005. Moreover, the Prana science continues to showpromise in the treatment of other diseases, such as Parkinson's disease."About Prana Biotechnology LimitedPrana Biotechnology was established to commercialize research into Alzheimer'sdisease and other major age-related degenerative disorders. The company wasincorporated in 1997 and listed on the Australian Stock Exchange in March 2000and listed on Nasdaq in September 2002. Researchers at prominent internationalinstitutions including the University of Melbourne and Massachusetts GeneralHospital, a teaching hospital of Harvard Medical School, discovered Prana'stechnology.For further information, please visit our web site at http://www.pranabio.com SOURCE Prana Biotechnology LimitedCONTACT: Kathy Price, Investor Relations Contact for Prana Biotechnology Limited, +1-212-983-1702 ext. 212, kprice@annemcbride.com; or Ivette Almeida, Media Relations contact for Prana Biotechnology Limited, +1-212-983-1702 ext. 209, ivette.almeida@annemcbride.com URL: http://www.pranabio.com http://www.prnewswire.comCopyright (C) 2004 PR Newswire. All rights reserved.KEYWORD: AustraliaINDUSTRY KEYWORD: HEA MTC BIO |
03.12.04 18:19
#49
geldschneider
Heute riesiges Umsatzvolumen
Das 10fache des sonsitgen Umsatzes!
109000 Stücke. Wow, was ist da im busch.
Schön wer schon investiert. Noch kann man sich günstige einkaufen.
gruß
moneymaker
109000 Stücke. Wow, was ist da im busch.
Schön wer schon investiert. Noch kann man sich günstige einkaufen.
gruß
moneymaker
03.12.04 19:32
#50
geldschneider
Buy, buy
120000 nun schon, was läuft da ab.
Und ichhabe immernochkeinen ECN Zugang. Ich bin am Verzweifeln.
Da geht heute was um so 20000 $ ordervolumen, ist keine Seltenheit.
Egal ich bin schon investiert, aber könnte gerne noch mehr von dem Kuchen haben.
Und ichhabe immernochkeinen ECN Zugang. Ich bin am Verzweifeln.
Da geht heute was um so 20000 $ ordervolumen, ist keine Seltenheit.
Egal ich bin schon investiert, aber könnte gerne noch mehr von dem Kuchen haben.
Seite:
1
|
1
|
2